Key facts
- It has raised $95.0M; the latest was Accelerator/Incubator in Jul 2024.
- Notable investors include High-Tech Gründerfonds, EDBI, NRW.Bank, Patient Square Capital, ABI LAB — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Resolve Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Resolve Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resolve Biosciences
Developer of molecular cartography platform designed to help scientists resolve biological challenges in areas such as oncology, neuroscience and infectious disease. The company's platform offers single-molecule detection technology, which allows full spatial context at subcellular resolution while preserving the sample tissue, enabling scientists to gain new insights based on the highest-resolution view of single-cell spatial biology.
- Sector
- Healthcare
- HQ
- Monheim am Rhein, Germany
- Founded
- 2019
- Employees
- 87
- Website
- resolvebiosciences.com/
- Ownership
- Privately Held (backing)
Resolve Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resolve Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resolve Biosciences in its N-PORT filings yet. We sweep new filings monthly.